tiprankstipranks
Advertisement

IQSM - ETF AI Analysis

Compare

Top Page

IQSM

IQ Candriam ESG U.S. Mid Cap Equity ETF (IQSM)

Rating:70Neutral
Price Target:
IQSM, the IQ Candriam ESG U.S. Mid Cap Equity ETF, has a solid overall rating that reflects generally strong underlying companies with some pockets of weakness. Key holdings like TechnipFMC, United Therapeutics, and Fabrinet support the fund’s quality through strong financial performance, positive earnings calls, and constructive growth outlooks, although their valuations can be on the high side. On the other hand, Revolution Medicines and MACOM Technology Solutions are weaker spots due to losses, unattractive valuations, and cash flow challenges, and a notable risk for the fund is exposure to several stocks with elevated valuations that could be more sensitive to market pullbacks.
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past month, indicating solid recent momentum.
Broad Sector Diversification
Holdings are spread across many sectors such as industrials, technology, health care, financials, and consumer-related areas, which helps reduce the impact of weakness in any single industry.
Low Expense Ratio
The fund’s relatively low annual fee means less of your return is eaten up by costs compared with many actively managed funds.
Negative Factors
U.S.-Only Geographic Exposure
Almost all of the ETF’s assets are invested in U.S. companies, offering little diversification across different countries and regions.
Mid-Cap Volatility Risk
Because the fund focuses on mid-sized companies, its share price may swing more than funds that hold larger, more established firms.
Sector Tilts Toward Industrials and Technology
The relatively heavy weighting in industrials and technology means the fund could be more affected if these sectors face a downturn.

IQSM vs. SPDR S&P 500 ETF (SPY)

IQSM Summary

IQ Candriam ESG U.S. Mid Cap Equity ETF (IQSM) tracks the NYLI Candriam U.S. Mid Cap Equity Index, focusing on medium‑sized U.S. companies that meet environmental, social, and governance (ESG) standards. It spreads money across many sectors like industrials, technology, and health care, with holdings such as Albemarle and Burlington Stores. Someone might invest in IQSM to seek long-term growth from mid-sized companies while also supporting more sustainable business practices. A key risk is that mid-cap stocks can be more volatile than large, well-known companies, so the value of this ETF can rise and fall significantly with the market.
How much will it cost me?The IQ Candriam ESG U.S. Mid Cap Equity ETF (Ticker: IQSM) has an expense ratio of 0.15%. This means you’ll pay $1.50 per year for every $1,000 invested. This expense ratio is lower than average because the fund is passively managed, tracking an index rather than relying on active management.
What would affect this ETF?The IQ Candriam ESG U.S. Mid Cap Equity ETF could benefit from growing interest in sustainable investing and the strong performance of mid-cap companies, particularly in sectors like technology and healthcare, which are well-represented in its holdings. However, potential risks include economic slowdowns or rising interest rates, which could negatively impact mid-cap stocks and sectors like consumer cyclical and real estate. Regulatory changes affecting ESG criteria or specific industries could also influence the ETF's future performance.

IQSM Top 10 Holdings

IQSM is leaning into U.S. mid-cap industrials and tech, with names like Sterling Infrastructure, MasTec, and MACOM doing much of the heavy lifting as their shares continue to climb. Twilio and Revolution Medicines add a punch of higher-risk growth, with Twilio’s rebound helping and Revolution’s more volatile biotech story a bit of a wild card. On the flip side, Albemarle has been losing steam lately, acting as a mild drag. Overall, the fund is broadly diversified across sectors but still very much a U.S.-centric, mid-cap growth-and-ESG play.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
TechnipFMC1.17%$3.84M$28.22B97.55%
80
Outperform
Twilio1.15%$3.78M$30.97B73.14%
70
Neutral
Revolution Medicines1.12%$3.69M$32.71B279.08%
52
Neutral
nVent Electric1.10%$3.60M$26.82B143.42%
76
Outperform
XPO1.08%$3.56M$26.81B80.11%
70
Outperform
Sterling Infrastructure1.06%$3.47M$26.36B323.17%
71
Outperform
MACOM Technology Solutions Holdings1.01%$3.32M$28.98B193.32%
64
Neutral
Fabrinet0.96%$3.17M$21.89B145.94%
78
Outperform
United Therapeutics0.96%$3.16M$23.17B92.68%
79
Outperform
MasTec0.96%$3.15M$28.68B127.31%
74
Outperform

IQSM Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
37.45
Positive
100DMA
36.58
Positive
200DMA
35.42
Positive
Market Momentum
MACD
0.39
Negative
RSI
63.54
Neutral
STOCH
90.99
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IQSM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.15, equal to the 50-day MA of 37.45, and equal to the 200-day MA of 35.42, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 63.54 is Neutral, neither overbought nor oversold. The STOCH value of 90.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IQSM.

IQSM Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$330.25M0.15%
70
Neutral
$917.32M0.38%
70
Neutral
$723.00M0.25%
71
Outperform
$652.50M0.04%
68
Neutral
$475.21M0.35%
75
Outperform
$448.41M0.24%
70
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IQSM
IQ Candriam ESG U.S. Mid Cap Equity ETF
39.10
7.72
24.60%
EZM
WisdomTree U.S. MidCap Fund
XMLV
Invesco S&P MidCap Low Volatility ETF
BKMC
BNY Mellon US Mid Cap Core Equity ETF
GRPM
Invesco S&P MidCap 400 GARP ETF
JPME
JPMorgan Diversified Return U.S. Mid Cap Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement